EXEL

EXEL

USD

Exelixis Inc. Common Stock

$37.900+0.090 (0.238%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$37.810

Máximo

$38.900

Mínimo

$37.582

Volume

2.81M

Fundamentos da empresa

Capitalização de mercado

10.2B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

2.62M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $31.9Atual $37.900Máximo $49.62

Notícias relacionadas

BusinessWire

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for

Ver mais
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Analyst Upgrades

Guggenheim Downgrades Exelixis to Neutral

Guggenheim analyst Michael W. Schmidt downgrades Exelixis from Buy to Neutral.

Ver mais
Guggenheim Downgrades Exelixis to Neutral
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are...

Ver mais
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
BusinessWire

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after

Ver mais
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44

Morgan Stanley analyst Sean Laaman maintains Exelixis with a Overweight and lowers the price target from $50 to $44.

Ver mais
Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
Analyst Upgrades

RBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target

RBC Capital analyst Leonid Timashev reiterates Exelixis with a Sector Perform and maintains $45 price target.

Analyst Upgrades

Wells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30

Wells Fargo analyst Derek Archila maintains Exelixis with a Equal-Weight and lowers the price target from $36 to $30.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.